The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: GVC Down 18% As Chiefs Sell 3 Million Shares

Fri, 08th Mar 2019 10:50

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Fresnillo, up 1.7%. The Mexican gold miner was tracking spot gold price higher, quoted at USD1,295.07 an ounce, up from USD1,285.30 at the London equities close Thursday. Mid-cap Egyptian miner Centamin was up 1.8%.----------GlaxoSmithKline, up 0.8%. The drugmaker said the Atlas and Flair studies showed that along-acting, injectable two-drug regimen in HIV-1 patients had similar efficacy to a daily three-drug treatment. Both phase three studies assessed a long-acting, injectable combination of cabotegravir and rilpivirine - injected every four weeks - and compared it against a standard of care, daily, three-drug regimen. 48-week data from both studies shows that they met their primary endpoints, showing that the two-drug regimen was not inferior in treating HIV. John Pottage, chief scientific & medical officer Of ViiV Healcare said: "With Flair and Atlas, we now have positive results from two pivotal phase three studies demonstrating that this long-acting, once-monthly injectable regimen has similar efficacy, safety and tolerability to a daily oral three-drug regimen for the treatment of HIV."----------FTSE 100 - LOSERS----------GVC Holdings, down 18% at 563.65 pence. GVC Chair Lee Feldman and Chief Executive Kenneth Alexander sold a significant amount of stock. Alexander sold 2.1 million shares at 666 pence for GBP13.7 million, while Feldman disposed of 900,000 shares at the same price for GBP6.0 million. Alexander said: "We have both held large personal shareholdings in GVC for a long time and continue to do so. Both of us remain fully committed to GVC and, whilst I continue to have the support of our shareholders, I'm here for the long term and at the very least I have a current plan that will take three plus years to accomplish."----------FTSE 250 - WINNERS----------SIG, up 9.1%. The building products supplier reported a drop in annual revenue, though it swung to a pretax profit. SIG's statutory revenue fell to GBP2.74 billion in 2018, from GBP2.88 billion in 2017, but it returned to pretax profit, posting GBP28.5 million from a GBP54.7 million loss a year prior. On an underlying basis, revenue fell 1.2% to GBP2.68 billion, with like-for-like sales down 2.1%. SIG's underlying pretax profit was up 8.5% to GBP75.3 million. SIG is paying a 2.5p final dividend, meaning the total for 2018 is unchanged from the year before at 3.75p. The company said its transformation strategy is now beginning to take shape, with the second half of 2018 seeing "significant" progress.----------Bodycote, up 7.2%. The thermal processing firm reported solid revenue and profit growth for 2018, with all of its divisions managing to report revenue improvement. The firm's statutory pretax profit climbed to GBP132.2 million from GBP117.0 million, with the headline figure up 12% to GBP136.4 million. Bodycote's revenue rose 5.6%, and 6.7% at constant currency rates, to GBP728.6 million. The company will pay a final dividend of 13.2p, taking the 2018 total to 19.0p from 17.4p a year before. On top of that, it also will pay a special dividend of 20p, having returned a special payout of 25p in 2017. Bodycote had a strong year, the company said, and it enters 2019 "well positioned".----------FTSE 250 - LOSERS----------Saga, down 9.0%. JPMorgan downgraded Saga to Underweight from Neutral, saying a weak balance sheet, alongside heightened insurance industry competition, could lead to concerns about the over 50s travel and insurance services provider's dividend. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Panthera Resources, up 20%. The miner reported positive developments from an investee, including a "significant" acquisition. Panthera has a 17% stake in Anglo Saxony Mining, a European explorer and developer with a flagship tin project in Tellerhauser, Germany. ASM's purchase is the Gottesberg tin deposit, 28 kilometres to the west of Tellerhauser, paid with both cash and shares. Gottesberg has a total resource of 42.1 million tonnes of ore at a grade of 0.27% tin, suggesting 113,000 tonnes of the commodity. Combining Gottesberg and Tellerhauser's resources, ASM now has a resource of 217,000 ounces of tin, which Panthera said is among the largest in the world. ----------Debenhams, up 13%. The troubled department store chain said it is "disappointed" that Sports Direct International has decided to requisition a general meeting to appoint Sports Direct boss Mike Ashley to the Debenhams board and remove all but one current board member. Debenhams added it has been engaging with both Sports Direct and other stakeholders regarding options to restructure the company's balance sheet. Sports Direct late Thursday said Founder & Chief Executive Ashley is seeking appointment to Debehmans board of directors. Ashley is aiming to be appointed to an executive role to focus on Debenhams business, including building a strong board and management team. Furthermore, Sports Direct is seeking to oust all Debenhams' board members with the exception of Rachel Osborne, who became a director in September 2018. If appointed, Ashley would step down from his current roles as a director & CEO of Sports Direct, which was down 0.5%.----------OTHER MAIN MARKET AND AIM - LOSERS----------Goals Soccer Centres, down 28%. The five-a-side football pitch operator said it expects 2018 results to be "materially below" expectations following discovery of accounting errors. Goals explained that results for the full year are now expected to be "materially below expectations" and delayed from their originally planned reporting date of March 12. This follows the firm - alongside its auditors - having to resolve some "accounting errors". Goals emphasised that the "majority" of these expected accounting adjustments are "non-cash" in nature. Despite this, the changes would mean that the firm will have "exceeded one of its banking covenants". Goals is currently discussing with the bank to agree new, renegotiated facilities. For the first two months of 2019, Goals reported trading had been "strong" with an increases in like-for-like sales on the prior year in both the UK and US.----------

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.